Scholarlink

Introduction <p>Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.</p> Methods <p>This French multicenter, cross-sectional study involved 21 ophthalmologists—members of the Board of Directors of the French Society of Glaucoma—from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma. The questionnaire collected data on demographics, treatment-related experiences, patient preferences, and the prioritization of six treatment criteria: cost, efficacy, dosing frequency, side effects, environmental impact, and ease of use.</p> Results <p>A total of 798 patients with glaucoma participated. There was no strong preference between multi-dose bottles and single-dose units (32.0% vs. 37.4%, respectively, with 29.2% of patients showing no preference). Side effects were reported by 31.8% of patients, and the use of artificial tears was significantly higher among those with longer treatment durations (31.3% for ≤ 2&#xa0;years vs. 65.6% for &gt; 20&#xa0;years, <i>p</i> = 0.001). Notably, 63% of patients were unaware that their eye drops could contain preservatives. Regarding generics, 29.9% of patients had previously used one, while only 25.6% were willing to switch from their prescribed brand to a generic equivalent. Adherence was suboptimal, with only 66.2% of patients reporting being compliant. Younger age (<i>p</i> &lt; 0.001) and lack of awareness about preservatives (<i>p</i> &lt; 0.001) were significantly associated with non-adherence. When ranking treatment criteria, patients prioritized efficacy, followed by side effects, ease of use, cost, and environmental impact.</p> Conclusion <p>This nationwide survey conducted by the French Glaucoma Society underscores the diversity of patient preferences and the critical need for personalized glaucoma care. A substantial proportion of patients feels insufficiently informed about preservatives and generics, which may negatively impact adherence. Enhanced patient education and individualized treatment strategies are essential for improving outcomes<b>.</b></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society

  • 期刊论文

  • 发表日期：

    2025年9月8日

查看全文
  • Paul Bastelica,
  • Antoine Labbe,
  • Marwan Sahyoun,
  • Christophe Baudouin,
  • Cédric Lamirel,
  • Muriel Poli,
  • Jean-Paul Renard,
  • Antoine Rousseau,
  • Cédric Schweitzer,
  • Florent Aptel

摘要

Introduction

Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.

Methods

This French multicenter, cross-sectional study involved 21 ophthalmologists—members of the Board of Directors of the French Society of Glaucoma—from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma. The questionnaire collected data on demographics, treatment-related experiences, patient preferences, and the prioritization of six treatment criteria: cost, efficacy, dosing frequency, side effects, environmental impact, and ease of use.

Results

A total of 798 patients with glaucoma participated. There was no strong preference between multi-dose bottles and single-dose units (32.0% vs. 37.4%, respectively, with 29.2% of patients showing no preference). Side effects were reported by 31.8% of patients, and the use of artificial tears was significantly higher among those with longer treatment durations (31.3% for ≤ 2 years vs. 65.6% for > 20 years, p = 0.001). Notably, 63% of patients were unaware that their eye drops could contain preservatives. Regarding generics, 29.9% of patients had previously used one, while only 25.6% were willing to switch from their prescribed brand to a generic equivalent. Adherence was suboptimal, with only 66.2% of patients reporting being compliant. Younger age (p < 0.001) and lack of awareness about preservatives (p < 0.001) were significantly associated with non-adherence. When ranking treatment criteria, patients prioritized efficacy, followed by side effects, ease of use, cost, and environmental impact.

Conclusion

This nationwide survey conducted by the French Glaucoma Society underscores the diversity of patient preferences and the critical need for personalized glaucoma care. A substantial proportion of patients feels insufficiently informed about preservatives and generics, which may negatively impact adherence. Enhanced patient education and individualized treatment strategies are essential for improving outcomes.